血静粉末的安全性和性能
Lukasz Szymanski1,2, Kamila Gołaszewska2, Justyna Małkowska2
1Department of Molecular Biology, Institute of Genetics and Animal Biotechnology, Polish Academy of Science, Magdalenka, 05-552, Poland.
Medical devices (Auckland, N.Z.)
|June 14, 2023
概括
4Seal血静粉具有卓越的安全性和性能,没有细胞毒性,并具有出色的吸水性和粘附性. 与其他经过测试的静血剂相比,它是实现恒常的最多功能选择.
科学领域:
- 生物材料科学 生物材料科学
- 创伤护理 创伤护理
- 医疗器械评估 医疗器械评估
背景情况:
- 流血是全球创伤相关死亡的主要原因.
- 静血粉对于实现血管快速关闭 (恒温) 是至关重要的.
- 这项研究评估了流行的静血粉末的安全性和有效性.
研究的目的:
- 为了比较领先的静血粉末的基本安全概况.
- 评估这些血液静止剂的体外性能特征.
- 根据安全性和功能来确定最通用的静血粉.
主要方法:
- 用MTT和MEM化试验评估了细胞毒性.
- 对每个产品的内毒素水平都被量化.
- 通过吸水能力,吸水率 (WAR) 和粘附强度评估体外性能.
主要成果:
- 4Seal,Starsil和4DryField没有表现出细胞毒性;PerClot,SuperClot和Arista表现出不同程度的细胞毒性.
- 4海表现出最低的内毒素污染.
- 4Seal和Starsil显示了最高的吸水率 (WAR),4Seal显示了最大的附着力.
结论:
- 4Seal提供了安全性和功能性质的最有利的组合.
- 在关键的安全性和性能指标上,它的表现优于4DryField,Arista,PerClot,Starsil和SuperClot.
- 4Seal被确定为评价的最通用的静血粉末.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
767
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
767
Introduction to Hemostasis
8.4K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
8.4K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
568
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
568
Disorders of Hemostasis
1.0K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.0K
Venous Thrombosis III: Interprofessional Care
11
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
11
Extrinsic and Intrinsic Pathways of Hemostasis
8.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.4K


